The Charles F. and Joanne Knight Alzheimer Disease Research Center (Knight ADRC) is one of approximately 30 Centers funded by the National Institute on Aging (NIA) through the following grants:

Alzheimer’s Disease Research Center (ADRC)
Project Period: 1985 – Present
View grant overview (PDF)

Antecedent Biomarkers for Alzheimer Disease: The Adult Children Study (ACS)
Project Period: 2005 – Present
View grant overview (PDF)

Dominantly Inherited Alzheimer Network (DIAN)
U19 AG0032438
Project Period: 2008 – Present

Healthy Aging and Senile Dementia (HASD)
Project Period: 1984 – Present
View grant overview (PDF)

The Knight ADRC, HASD, ACS and DIAN engage faculty and staff from the Department of Neurology and other departments at Washington University in the study of cognitive aging and dementia. Alzheimer disease (AD) is a central focus of both research and education. These primary grants provide the core data acquisition and management structures for numerous other research efforts by investigators at Washington University. John C. Morris, MD, Friedman Distinguished Professor of Neurology, is the Principal Investigator of HASD, ADRC, and ACS.  Randall Bateman, MD, Charles F. and Joanne Knight Distinguished Professor of Neurology, is the Principal Investigator of DIAN.

Research efforts through the Knight ADRC and HASD focus on identifying causal and risk factor mechanisms in the development of AD and other dementias, biochemical and clinical-behavioral indicators of disease onset and progression, and potential therapeutic and preventative agents. Research participants and family members take part in annual, longitudinal assessments through the Knight ADRC’s clinical office, the Memory and Aging Project (MAP). MAP participants also are invited to take part in various ancillary studies supported by the Knight ADRC, and provide biological and imaging specimens for basic research projects in affiliated laboratories across the University.

The Adult Children Study (ACS) builds on and focuses work conducted through the Knight ADRC and HASD over the past two decades, with a goal of identifying antecedent biomarkers for the early and preclinical detection of AD.